Non-coding RNAs: Therapeutic strategies and delivery systems

Advances in Experimental Medicine and Biology

Volumn 937, Issue , 2016, Pages 229-237

  Ling, Hui ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anti miR; Colorectal cancer; Delivery; Long noncoding RNA; MicroRNA; Mimics; Therapeutics

Indexed keywords

ANTAGOMIR; ANTISENSE OLIGODEOXYNUCLEOTIDE; AZACITIDINE; DECITABINE; DEOXYRIBOZYME; LOCKED NUCLEIC ACID; MACROGOL; MIRAVIRSEN; RIBOZYME; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; UNTRANSLATED RNA; ANTISENSE OLIGONUCLEOTIDE; DRUG VEHICLE; LIPOSOME; LONG UNTRANSLATED RNA; MICRORNA; RNA;

ANTISENSE THERAPY; ARTICLE; COLORECTAL CANCER; DRUG ANTAGONISM; GENE CONTROL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENE VECTOR; HUMAN; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RNA DEGRADATION; RNA TRANSCRIPTION; RNA TRANSLATION; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; FORECASTING; GENETICS; MOLECULARLY TARGETED THERAPY; PROCEDURES;

COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FORECASTING; HUMANS; LIPOSOMES; MICRORNAS; MOLECULAR TARGETED THERAPY; OLIGONUCLEOTIDES, ANTISENSE; PHARMACEUTICAL VEHICLES; RNA, CATALYTIC; RNA, LONG NONCODING; RNA, NEOPLASM; RNA, SMALL INTERFERING; RNA, UNTRANSLATED;

EID: 84985017275     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-42059-2_12     Document Type: Article

References (29)

1. Rosenbloom KR, Dreszer TR, Long JC, Malladi VS, Sloan CA, Raney BJ, et al. ENCODE whole-genome data in the UCSC Genome Browser: update 2012. Nucleic Acids Res. 2012;40(Database issue):D912–7. Epub 2011/11/15.
2. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12(11):847–65. Epub 2013/11/01.
3. Wan Y, Qu K, Zhang QC, Flynn RA, Manor O, Ouyang Z, et al. Landscape and variation of RNA secondary structure across the human transcriptome. Nature. 2014;505(7485):706–9. Epub 2014/01/31.
4. Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther. 2011;18(12):1121–6. Epub 2011/06/03.
5. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007;67(4):1424–9. Epub 2007/02/20.
6. Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, et al. Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer. 2009;125(11):2737–43. Epub 2009/06/13.
7. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle. 2006;5(19):2220–2. Epub 2006/10/03.
8. Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C, et al. Small molecule enoxacin is a cancerspecific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A. 2011;108(11):4394–9. Epub 2011/03/04.
9. Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol. 2013;31(7):577. Epub 2013/07/11.
10. Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 2011;18(12):1111–20. Epub 2011/07/15.
11. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368(18):1685–94. Epub 2013/03/29.
12. Lieberman J, Sarnow P. Micromanaging hepatitis C virus. N Engl J Med. 2013;368(18):1741–3. Epub 2013/03/29.
13. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet. 2011;43(4):371–8. Epub 2011/03/23.
14. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438(7068):685–9. Epub 2005/11/01.
15. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007;4(9):721–6. Epub 2007/08/19.
16. Xie J, Ameres SL, Friedline R, Hung JH, Zhang Y, Xie Q, et al. Long-term, efficient inhibition of microRNA function in mice using rAAV vectors. Nat Methods. 2012;9(4):403–9. Epub 2012/03/06.
17. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al. Many human large intergenic noncoding RNAs associate with chromatinmodifying complexes and affect gene expression. Proc Natl Acad Sci U S A. 2009;106(28):11667–72. Epub 2009/07/03.
18. Wahlestedt C. Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov. 2013;12(6):433–46. Epub 2013/06/01.
19. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967–77. Epub 2013/10/24.
20. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505–15. Epub 2008/08/05.
21. Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther. 2012;20(3):513–24. Epub 2012/01/19.
22. Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta. 2011;1816(2):232–46. Epub 2011/08/16.
23. Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 2015;518(7537):107–10. Epub 2014/11/20.
24. Alabi C, Vegas A, Anderson D. Attacking the genome: emerging siRNA nanocarriers from concept to clinic. Curr Opin Pharmacol. 2012;12(4):427–33. Epub 2012/06/26.
25. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J. 2011;6(9):1130–46. Epub 2011/07/12.
26. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3(4):406–17. Epub 2013/01/30.
27. Dvinge H, Git A, Graf S, Salmon-Divon M, Curtis C, Sottoriva A, et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013;497(7449):378–82. Epub 2013/05/07.
28. Gindy ME, Leone AM, Cunningham JJ. Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics. Expert Opin Drug Deliv. 2012;9(2):171–82. Epub 2012/01/19.
29. Melo SA, Sugimoto H, O’Connell JT, Kato N, Villanueva A, Vidal A, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26(5):707–21. Epub 2014/12/03.